All In Biotech

Drug Trial Radar · NCT04384484

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

440

Actual

Start

Sep 16, 2020

Primary completion

Mar 31, 2026

Study completion Jun 30, 2028

Sponsor

Lead sponsor
ADC Therapeutics S.A.Industry
Sponsor type
Industry
First posted
May 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Conditions

  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma

Interventions

  • Loncastuximab TesirineDrug

    Intravenous Infusion

  • RituximabDrug

    Intravenous Infusion

  • GemcitabineDrug

    Intravenous Infusion

  • OxaliplatinDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to 4 years

Locations

144 sites in 21 countries. Site status is shown where the registry gives one.

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • Redlands Community Hospital

    Redlands, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • UnityPoint Health - Iowa Oncology Research Association (IORA)

    Des Moines, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • Comprehensive Cancer Centers of Nevada - Henderson

    Las Vegas, Nevada

  • Kaiser Permanente Interstate Medical Office Central

    Portland, Oregon

  • Hollings Cancer Center

    Charleston, South Carolina

  • Virginia Cancer Specialists

    Gainesville, Virginia

  • Medical College of Wisconsin Cancer Center Clinical Trials Office

    Milwaukee, Wisconsin

  • Clinica Adventista Belgrano

    Belgrano, Buenos Aires, Argentina

  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares S.A.

    Santa Fe, Buenos Aires, Argentina

  • Instituto Médico Especializado Alexander Fleming

    Buenos Aires, Distrito Federal, Argentina

  • Grupo Gamma - Hospital Privado Rosario

    Rosario, Santa Fe Province, Argentina

  • Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan

    Bruges, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Centre Hospitalier Universitaire Universite Catholique de Louvain

    Namur, Belgium

  • Algemeen Ziekenhuis Delta - Campus Rumbeke

    Roeselare, Belgium

  • Hospital do Câncer

    Rio de Janeiro, Brazil

  • Hemomed Instituto de Oncologia e Hematologia

    São Paulo, Brazil

  • A Beneficência Portuguesa de São Paulo - Unidade Mirante

    São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Hospital Santa Marcelina

    São Paulo, Brazil

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

    Curitiba, Paraná, Brazil

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Mãe de Deus - Centro Integrado de Oncologia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Cross Cancer Institute

    Edmonton, Canada

  • Research Institute of the McGill University Health Centre

    Montreal, Canada

  • Hôpital Fleurimont

    Sherbrooke, Canada

  • Centro de Estudios Clínicos SAGA

    Santiago, Santiago Metropolitan, Chile

  • Instituto Oncológico Fundación Arturo López Pérez

    Santiago, Santiago Metropolitan, Chile

  • CeCim - Centro de Estudios Clínicos e Investigaciones Médicas

    Santiago, Santiago Metropolitan, Chile

  • Chongqing University Cancer Hospital - Chongqing Cancer Hospital

    Chongqing, China

  • Huizhou Municipal Central Hospital

    Huizhou, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Institute of Hematology and Blood Diseases Hospital of CAMS - PUMC

    Tianjin, China

  • Wuhan Union Hospital

    Wuhan, China

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.